FAMILY MEDICINE – SLEEP MEDICINE CERTIFICATED
NEWEST EXAM FOR THE AMERICAN BOARD OF FAMILY
MEDICINE (ABMS) | Q&A WITH RATIONALES
This high-yield exam preparation resource features a comprehensive
bank of multiple-choice questions matching the American Board of Family
Medicine (ABFM) Sleep Medicine blueprint. Each entry delivers verified
answers and detailed clinical rationales designed to solidify
understanding of sleep architecture, diagnostic criteria, and management
protocols. It is the ultimate study guide optimized to help medical
residents, fellows, and practicing physicians maximize their scores on
high-stakes board exams.
Question 1
A 45-year-old male with a BMI of 34 kg/m² presents with severe daytime
sleepiness and loud snoring. A diagnostic polysomnography (PSG)
demonstrates an Apnea-Hypopnea Index (AHI) of 42 events/hour. CPAP
titration successfully eliminates obstructive events at 10 cm H2O.
However, during the titration, the patient develops central apneas with a
central AHI of 18 events/hour that persist for more than 3 hours of the
study. What is the most appropriate next step in clinical management?
, A. Switch immediately to Bilevel Positive Airway Pressure (BPAP) in
spontaneous mode
B. Continue CPAP at 10 cm H2O as treatment-emergent central sleep
apnea often resolves over time
C. Initiate Adaptive Servo-Ventilation (ASV)
D. Discontinue PAP therapy and refer for maxillomandibular
advancement
ANSWER: B. Continue CPAP at 10 cm H2O as treatment-emergent
central sleep apnea often resolves over time
RATIONALE: Treatment-emergent central sleep apnea (TE-CSA),
formerly known as complex sleep apnea, occurs when obstructive
events are cleared with positive airway pressure (PAP), but central
apneas emerge or persist. In the vast majority of patients, TE-CSA is
transient and resolves spontaneously within 4 to 8 weeks of
continued CPAP compliance. Extrapolating or switching to advanced
modalities like ASV or BPAP prematurely is not indicated unless the
central apneas persist long-term and cause significant
desaturations or sleep fragmentation.
Question 2
A 28-year-old female presents with a 6-month history of severe daytime
sleepiness despite sleeping 8 to 9 hours per night. She reports brief
,episodes of sudden bilateral knee weakness triggered by hearing a funny
joke. A overnight PSG shows a total sleep time of 510 minutes with a sleep
efficiency of 91% and an AHI of 2 events/hour. A Multiple Sleep Latency
Test (MSLT) performed the following day demonstrates a mean sleep
latency of 4.5 minutes and 3 Sleep Onset REM Periods (SOREMPs). Which
of the following cerebrospinal fluid (CSF) findings is most diagnostic for
this condition?
A. Elevated total protein with normal cell count
B. Decreased Orexin-A (Hypocretin-1) levels \(\le \) 110 pg/mL
C. Elevated 5-hydroxyindoleacetic acid (5-HIAA)
D. Decreased Tau protein levels
ANSWER: B. Decreased Orexin-A (Hypocretin-1) levels \(\le \) 110
pg/mL
RATIONALE: The patient clinical triad of severe daytime sleepiness,
clear cataplexy (knee weakness triggered by emotion), and MSLT
objective findings (mean sleep latency < 8 minutes and \(\ge \) 2
SOREMPs) confirms a diagnosis of Narcolepsy Type 1. Narcolepsy
Type 1 is caused by the autoimmune destruction of hypocretin-
producing neurons in the lateral hypothalamus. A CSF Orexin-A
(Hypocretin-1) concentration of \(\le \) 110 pg/mL (or less than
one-third of mean normal control values) is highly specific and
definitive for Narcolepsy Type 1.
, Question 3
A 68-year-old male is brought to the clinic by his wife, who reports that
he frequently "acts out his dreams" by punching, kicking, and shouting
during the last third of the night. During a recent episode, he accidentally
struck his nightstand, causing a laceration to his hand. An overnight PSG
shows a lack of normal skeletal muscle hypotonia/atonia during REM
sleep, accompanied by excessive muscle twitching on the submental
electromyogram (EMG). What is the first-line pharmacotherapy for this
condition if environmental safety measures alone are insufficient?
A. Pramipexole
B. Melatonin
C. Modafinil
D. Haloperidol
ANSWER: B. Melatonin
RATIONALE: This patient presents with REM Sleep Behavior Disorder
(RBD), characterized by the loss of normal REM sleep muscle atonia,
leading to motor dream enactment. The first and most critical
management step is establishing environmental safety (e.g.,
removing sharp objects, placing cushions next to the bed). When
pharmacotherapy is required due to ongoing risk of injury, high-
dose Melatonin (3–12 mg at bedtime) is recommended as a first-line
agent due to its excellent safety profile, especially in elderly
individuals. Clonazepam is also highly effective but carries a higher
NEWEST EXAM FOR THE AMERICAN BOARD OF FAMILY
MEDICINE (ABMS) | Q&A WITH RATIONALES
This high-yield exam preparation resource features a comprehensive
bank of multiple-choice questions matching the American Board of Family
Medicine (ABFM) Sleep Medicine blueprint. Each entry delivers verified
answers and detailed clinical rationales designed to solidify
understanding of sleep architecture, diagnostic criteria, and management
protocols. It is the ultimate study guide optimized to help medical
residents, fellows, and practicing physicians maximize their scores on
high-stakes board exams.
Question 1
A 45-year-old male with a BMI of 34 kg/m² presents with severe daytime
sleepiness and loud snoring. A diagnostic polysomnography (PSG)
demonstrates an Apnea-Hypopnea Index (AHI) of 42 events/hour. CPAP
titration successfully eliminates obstructive events at 10 cm H2O.
However, during the titration, the patient develops central apneas with a
central AHI of 18 events/hour that persist for more than 3 hours of the
study. What is the most appropriate next step in clinical management?
, A. Switch immediately to Bilevel Positive Airway Pressure (BPAP) in
spontaneous mode
B. Continue CPAP at 10 cm H2O as treatment-emergent central sleep
apnea often resolves over time
C. Initiate Adaptive Servo-Ventilation (ASV)
D. Discontinue PAP therapy and refer for maxillomandibular
advancement
ANSWER: B. Continue CPAP at 10 cm H2O as treatment-emergent
central sleep apnea often resolves over time
RATIONALE: Treatment-emergent central sleep apnea (TE-CSA),
formerly known as complex sleep apnea, occurs when obstructive
events are cleared with positive airway pressure (PAP), but central
apneas emerge or persist. In the vast majority of patients, TE-CSA is
transient and resolves spontaneously within 4 to 8 weeks of
continued CPAP compliance. Extrapolating or switching to advanced
modalities like ASV or BPAP prematurely is not indicated unless the
central apneas persist long-term and cause significant
desaturations or sleep fragmentation.
Question 2
A 28-year-old female presents with a 6-month history of severe daytime
sleepiness despite sleeping 8 to 9 hours per night. She reports brief
,episodes of sudden bilateral knee weakness triggered by hearing a funny
joke. A overnight PSG shows a total sleep time of 510 minutes with a sleep
efficiency of 91% and an AHI of 2 events/hour. A Multiple Sleep Latency
Test (MSLT) performed the following day demonstrates a mean sleep
latency of 4.5 minutes and 3 Sleep Onset REM Periods (SOREMPs). Which
of the following cerebrospinal fluid (CSF) findings is most diagnostic for
this condition?
A. Elevated total protein with normal cell count
B. Decreased Orexin-A (Hypocretin-1) levels \(\le \) 110 pg/mL
C. Elevated 5-hydroxyindoleacetic acid (5-HIAA)
D. Decreased Tau protein levels
ANSWER: B. Decreased Orexin-A (Hypocretin-1) levels \(\le \) 110
pg/mL
RATIONALE: The patient clinical triad of severe daytime sleepiness,
clear cataplexy (knee weakness triggered by emotion), and MSLT
objective findings (mean sleep latency < 8 minutes and \(\ge \) 2
SOREMPs) confirms a diagnosis of Narcolepsy Type 1. Narcolepsy
Type 1 is caused by the autoimmune destruction of hypocretin-
producing neurons in the lateral hypothalamus. A CSF Orexin-A
(Hypocretin-1) concentration of \(\le \) 110 pg/mL (or less than
one-third of mean normal control values) is highly specific and
definitive for Narcolepsy Type 1.
, Question 3
A 68-year-old male is brought to the clinic by his wife, who reports that
he frequently "acts out his dreams" by punching, kicking, and shouting
during the last third of the night. During a recent episode, he accidentally
struck his nightstand, causing a laceration to his hand. An overnight PSG
shows a lack of normal skeletal muscle hypotonia/atonia during REM
sleep, accompanied by excessive muscle twitching on the submental
electromyogram (EMG). What is the first-line pharmacotherapy for this
condition if environmental safety measures alone are insufficient?
A. Pramipexole
B. Melatonin
C. Modafinil
D. Haloperidol
ANSWER: B. Melatonin
RATIONALE: This patient presents with REM Sleep Behavior Disorder
(RBD), characterized by the loss of normal REM sleep muscle atonia,
leading to motor dream enactment. The first and most critical
management step is establishing environmental safety (e.g.,
removing sharp objects, placing cushions next to the bed). When
pharmacotherapy is required due to ongoing risk of injury, high-
dose Melatonin (3–12 mg at bedtime) is recommended as a first-line
agent due to its excellent safety profile, especially in elderly
individuals. Clonazepam is also highly effective but carries a higher
